CAJ | 학술논문

胃肠道间质瘤（GIST）是胃肠道最常见的间叶源性肿瘤，占间叶源性肿瘤的18%和消化道肿瘤的1%，每年发病率为1/10万~2/10万。恶性 GIST 根治性切除术后5年复发率高达50%，转移性 GIST 既往中位生存期仅9个月。目前，对直径≤2 cm 的上消化道 GIST 首选内镜超声（EUS）检查，直径>2 cm 的 GIST 因恶变程度高，首选手术切除，对于手术切除困难、风险高的病灶可选择酪氨酸激酶抑制剂辅助化疗和新辅助化疗。本文就 GIST 的治疗进展作一综述。
위장도간질류（GIST）시위장도최상견적간협원성종류，점간협원성종류적18%화소화도종류적1%，매년발병솔위1/10만~2/10만。악성 GIST 근치성절제술후5년복발솔고체50%，전이성 GIST 기왕중위생존기부9개월。목전，대직경≤2 cm 적상소화도 GIST 수선내경초성（EUS）검사，직경>2 cm 적 GIST 인악변정도고，수선수술절제，대우수술절제곤난、풍험고적병조가선택락안산격매억제제보조화료화신보조화료。본문취 GIST 적치료진전작일종술。
Gastrointestinal stromal tumor( GIST)is the most common gastrointestinal mesenchymal neoplasm and accounts approximately 18% of all mesenchymal neoplasms and 1% of all gastrointestinal neoplasms. Morbidity of GIST is about 1-2 per hundred thousand per year. The recurrence rate 5 years after complete resection of malignant GIST is up to 50%,and the median survival of metastatic GIST is only 9 months. Nowadays,endoscopic ultrasonography(EUS)is the first choice management for upper digestive tract GIST with diameter ≤2 cm,however,because of its high degree malignancy,surgical resection is the choice for GIST with diameter > 2 cm,and adjuvant or neoadjuvant chemotherapy with tyrosine kinase inhibitors can be used in case with high risks and difficulties in surgical removal. This article reviewed the advances in study on treatment of GIST.